

Murtadha Al-Khabori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802435/publications.pdf>

Version: 2024-02-01

281
papers

5,143
citations

109264

35
h-index

128225

60
g-index

288
all docs

288
docs citations

288
times ranked

6313
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients'™ knowledge and awareness of safe handling of oral anticancer agents at Sultan Qaboos University Hospital in Oman. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 112-118.	0.5	1
2	Measurement of hematopoietic progenitor cells using XN2000 hematology analyzer. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 82-87.	0.7	2
3	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	1.7	87
4	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	1.3	4
5	Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 105.e1-105.e7.	0.6	5
6	HEV infection in stem cell transplant recipients'™ retrospective study of EBMT Infectious Diseases Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 167-175.	1.3	6
7	Molecular blood group screening in Omani blood donors. <i>Vox Sanguinis</i> , 2022, 117, 424-430.	0.7	1
8	Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231.	1.3	5
9	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
10	Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 527-534.	1.0	2
11	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	3.2	12
12	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation'™ study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	1.3	4
13	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	1.3	2
14	The added value of multi'™state modelling in a randomized controlled trial: The HOVON 102 study re'™analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	1.3	3
15	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	1.3	4
16	Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production. <i>PLoS ONE</i> , 2022, 17, e0267662.	1.1	4
17	Ibrutinib dose intensity in high'™risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104.	0.8	1
18	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
20	The Survey on Cellular and Tissue-Engineered Therapies in Europe in 2016 and 2017. <i>Tissue Engineering - Part A</i> , 2021, 27, 336-350.	1.6	3
21	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
22	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	2.0	40
23	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 1190-1199.	1.3	16
24	Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 693-701.	0.5	9
25	Patient preferences for allogeneic haematopoietic stem cell transplantation: how much benefit is worthwhile from the patient's perspective?. <i>Supportive Care in Cancer</i> , 2021, 29, 3129-3135.	1.0	1
26	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021, 223, 1564-1575.	1.9	21
27	Current evidence and the emerging role of eltrombopag in severe aplastic anemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072199812.	1.1	20
28	Antenatal predictors of stem cell content for successful umbilical cord blood donation. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 377-384.	0.8	0
29	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	2.5	33
30	Current practice of oral care for hematopoietic stem cell transplant patients: A survey of the Eastern Mediterranean Blood and Marrow transplantation group. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	3
31	Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. <i>British Journal of Haematology</i> , 2021, 192, e151-e154.	1.2	3
32	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	0.8	5
33	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	1.3	7
34	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1513.	3.8	24
35	Correlation of expression of Akt1 and E2F1 and their phosphorylated forms in breast cancer patients with clinicopathological parameters. <i>Journal of Molecular Histology</i> , 2021, 52, 621-633.	1.0	3
36	An ounce of which prevention is worth a€?. <i>Blood</i> , 2021, 137, 1852-1853.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. <i>Bone Marrow Transplantation</i> , 2021, 56, 2144-2151.	1.3	16
38	Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e334-e343.	2.2	20
39	Legionellosis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2555-2566.	1.3	1
40	Circulating activated neutrophils in COVID-19: An independent predictor for mechanical ventilation and death. <i>International Journal of Infectious Diseases</i> , 2021, 106, 155-159.	1.5	36
41	A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7053-TPS7053.	0.8	0
42	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. <i>Leukemia</i> , 2021, 35, 3551-3560.	3.3	40
43	Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 2518-2522.	1.3	7
44	Balancing risk in a patient with primary bone histiocytic sarcoma during pregnancy: Case report and review of the literature. <i>International Journal of Surgery Case Reports</i> , 2021, 83, 106021.	0.2	0
45	Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1913-1915.	0.8	0
46	Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2011-2015.	0.3	1
47	Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman. <i>Journal of Infection and Public Health</i> , 2021, 14, 1578-1584.	1.9	7
48	Proteomics: Concepts and applications in human medicine. <i>World Journal of Biological Chemistry</i> , 2021, 12, 57-69.	1.7	75
49	Immunological predictors of disease severity in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 110, 83-92.	1.5	12
50	Influence of HLA-DPB1 mismatches on outcome after allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2021, 16, 100259.	0.2	1
51	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
52	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 701-711.	0.3	8
53	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. <i>Blood</i> , 2021, 138, 1745-1745.	0.6	2
54	Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT. <i>Blood</i> , 2021, 138, 1822-1822.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
56	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	1.1	7
57	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	1.3	13
58	Optimal Treatment Duration of <i>Pseudomonas aeruginosa</i> Infections in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa246.	0.4	7
59	Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation – A Single Centre Study. <i>Anticancer Research</i> , 2020, 40, 5909-5917.	0.5	12
60	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis. <i>Lancet Haematology</i> , 2020, 7, e364.	2.2	0
61	Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. <i>Blood Advances</i> , 2020, 4, 3699-3707.	2.5	17
62	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
63	Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 249.	1.2	8
64	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	2.5	12
65	Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease Classification. <i>Translational Vision Science and Technology</i> , 2020, 9, 3.	1.1	13
66	Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.6	0
67	Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 112, 210-216.	0.7	4
68	Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 190, 437-441.	1.2	4
69	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	2.8	40
70	Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. <i>Annals of Hematology</i> , 2020, 99, 2009-2017.	0.8	8
71	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
72	Efficiency of day 4 compared to day 6 stem cell mobilization in allogeneic stem cell donors. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102727.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	1.3	78
74	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	1.7	34
75	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1906-1917.	1.3	33
76	Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera. <i>Journal of Hematopathology</i> , 2020, 13, 105-107.	0.2	4
77	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1763-1772.	1.3	14
78	Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best perceived in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1847-1850.	1.3	9
79	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13289.	0.7	11
80	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	1.3	3
81	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the CmwP EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
82	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
83	Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis. <i>Blood</i> , 2020, 136, 38-39.	0.6	1
84	Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT). <i>Blood</i> , 2020, 136, 6-7.	0.6	0
85	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. <i>Bone Marrow Transplantation</i> , 2019, 54, 402-417.	1.3	31
86	High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 540-548.	1.3	49
87	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	1.3	59
88	Biological markers of hemostasis and endothelial activation in patients with a hematological malignancy with or without stem cell transplants. <i>European Journal of Haematology</i> , 2019, 103, 472-477.	1.1	8
89	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	2.0	9
90	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2008-2016.	2.0	20

#	ARTICLE	IF	CITATIONS
91	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
92	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	1.3	6
93	Common oral diseases, hyposalivation and survival postâ€”HSCT, a longitudinal study. <i>European Journal of Haematology</i> , 2019, 103, 300-306.	1.1	10
94	Impact of cell saver during cardiac surgery on blood transfusion requirements: a systematic review and metaâ€”analysis. <i>Vox Sanguinis</i> , 2019, 114, 553-565.	0.7	8
95	Successful Management of Endometriosis, <i>In Vitro</i> Fertilization, Pregnancy, and Postpartum Recovery in a Woman with Glanzmann's Thrombasthenia. <i>Journal of Gynecologic Surgery</i> , 2019, 35, 321-323.	0.0	2
96	Clinical impact of amotosalenâ€”ultraviolet A pathogenâ€”inactivated platelets stored for up to 7â€”days. <i>Transfusion</i> , 2019, 59, 3350-3361.	0.8	19
97	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
98	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	1.7	12
99	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	0.8	35
100	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	0.8	30
101	High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1701-1709.	1.3	15
102	Sorafenib improves survival of <i>FLT3</i> -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	1.7	46
103	Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1651-1661.	1.3	15
104	Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0225099.	1.1	8
105	Cyclosporine levels $\geq 195 \mu\text{g/L}$ on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 971-977.	0.8	17
106	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
107	Noninvasive assessment and risk factors of liver fibrosis in patients with thalassemia major using shear wave elastography. <i>Hematology</i> , 2019, 24, 183-188.	0.7	16
108	Common oral diseases in allogeneic haematopoietic stem cell transplantation (HSCT) recipients preâ€”HSCT. <i>European Journal of Haematology</i> , 2019, 102, 351-356.	1.1	9

#	ARTICLE	IF	CITATIONS
109	Obstacles to Widening Biosample Research. <i>Science and Engineering Ethics</i> , 2019, 25, 113-128.	1.7	3
110	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	1.2	7
111	Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01). <i>Blood</i> , 2019, 134, 614-614.	0.6	7
112	Impact of Home-to-Centre Distance on Bone Marrow Transplantation Outcomes. <i>Sultan Qaboos University Medical Journal</i> , 2019, 19, 15.	0.3	2
113	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. <i>Swiss Medical Weekly</i> , 2019, 149, w20150.	0.8	3
114	Impact of Blood Transfusion on Troponin I Levels and Outcomes after Cardiac Surgery: A Cohort Study. <i>Oman Medical Journal</i> , 2019, 34, 14-19.	0.3	2
115	Outcome of Late-onset Neonatal Sepsis at a Tertiary Hospital in Oman. <i>Oman Medical Journal</i> , 2019, 34, 302-307.	0.3	10
116	Prevalence of Red Blood Cell Major Blood Group Antigens and Phenotypes among Omani Blood Donors. <i>Oman Medical Journal</i> , 2019, 34, 496-503.	0.3	12
117	Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis. <i>Oman Medical Journal</i> , 2019, 34, 434-437.	0.3	8
118	Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 5383-5383.	0.6	2
119	Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease. <i>Blood</i> , 2019, 134, 4831-4831.	0.6	0
120	Clinical and Magnetic Resonance Imaging (MRI) Decision Making Rules in Differentiating Vaso-Occlusive Crises (VOCs) from Osteomyelitis in Paediatric Sickle Cell Population: Is MRI Pathognomonic?. <i>Blood</i> , 2019, 134, 4824-4824.	0.6	0
121	Prevalence, Clinical Characteristics and Outcome of Von Willebrand Disease in Oman. <i>Blood</i> , 2019, 134, 4939-4939.	0.6	0
122	"Prevalence and Outcome of Avascular Necrosis of the Hip (AVN) Among Young Omani Patients with Sickle Cell Disease". <i>Blood</i> , 2019, 134, 3577-3577.	0.6	0
123	Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 2604-2604.	0.6	0
124	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	2.0	30
125	Recombinant factor XIII A β subunit in a patient with factor XIII deficiency and recurrent pregnancy loss. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1052-1054.	1.9	2
126	Anti- α thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia α -negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2018, 124, 2523-2533.	2.0	18

#	ARTICLE	IF	CITATIONS
127	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. <i>Cytotherapy</i> , 2018, 20, 453-460.	0.3	14
128	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	1.7	18
129	Stability of fetal hemoglobin levels in patients receiving metformin therapy. <i>Haematologica</i> , 2018, 103, e440-e442.	1.7	4
130	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	0.6	43
131	The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. <i>Cytotherapy</i> , 2018, 20, 1-20.	0.3	12
132	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
133	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	1.7	82
134	Combined Factor V and VIII Deficiency. <i>Oman Medical Journal</i> , 2018, 33, 268-268.	0.3	1
135	Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment. <i>Frontiers in Oncology</i> , 2018, 8, 587.	1.3	49
136	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	6.9	17
137	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 1532-1542.	2.0	10
138	Transfusion knowledge of medical and surgical specialty board residents: a cohort study. <i>Transfusion Medicine</i> , 2018, 28, 440-450.	0.5	4
139	What the internist should know about stem cell transplant in the elderly patient. <i>European Journal of Internal Medicine</i> , 2018, 58, 43-47.	1.0	0
140	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1211-1219.	2.0	20
141	Immunoglobulin G4-Related Disease: An Update. <i>Oman Medical Journal</i> , 2018, 33, 97-103.	0.3	29
142	Severe anemia after trans-catheter arterial chemoembolization – an unusual presentation of hemoglobin Zurich. <i>Annals of Hematology</i> , 2018, 97, 2249-2251.	0.8	0
143	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12981.	0.7	35
144	Diagnosis of invasive mold diseases in patients with hematological malignancies using <i>Aspergillus</i> , <i>Mucorales</i> and panfungal <i>PCR</i> in <i>BAL</i> . <i>Transplant Infectious Disease</i> , 2018, 20, e12953.	0.7	19

#	ARTICLE	IF	CITATIONS
145	The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes. <i>Blood</i> , 2018, 132, 2391-2391.	0.6	1
146	Knowledge and Attitudes Towards Clinical Trial Participation in Oman: A cross-sectional study. <i>Sultan Qaboos University Medical Journal</i> , 2018, 18, 54.	0.3	10
147	Immunophenotypic Characteristics of T-Acute Lymphoblastic Leukemia in Omani Patients: A Correlation with Demographic Factors. <i>Oman Medical Journal</i> , 2018, 33, 43-47.	0.3	2
148	Understanding Iron Metabolism: Lessons from Transfusion-dependent Thalassemia. <i>Oman Medical Journal</i> , 2018, 33, 1-2.	0.3	1
149	Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21069-e21069.	0.8	0
150	Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7045-7045.	0.8	0
151	The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study. <i>Blood</i> , 2018, 132, 5369-5369.	0.6	0
152	Incorporation of Clinical Information to Decipher Driver Mutations in Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 5489-5489.	0.6	0
153	Incorporation of Evidence Based Guidelines on Bleeding Risk Assessment PRIOR to Ent Surgery into Practice: Real Time Experience. <i>Blood</i> , 2018, 132, 4714-4714.	0.6	0
154	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017, 129, 1636-1645.	0.6	77
155	Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure. <i>Annals of Hematology</i> , 2017, 96, 703-705.	0.8	9
156	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
157	Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. <i>Haematologica</i> , 2017, 102, e271-e274.	1.7	9
158	Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 58, 43-47.	0.4	19
159	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	2.0	34
160	Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 70-78.	0.6	19
161	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <sc>CLL</sc>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	1.2	26
162	Fungemia and necrotic lymph node infection with <i>Sporopachydermia cereana</i> in a patient with acute myeloid leukemia. <i>International Journal of Infectious Diseases</i> , 2017, 61, 103-106.	1.5	2

#	ARTICLE	IF	CITATIONS
163	Hematopoietic stem cell transplantation in the Sultanate of Oman. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 305-307.	0.6	7
164	Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. <i>Nutrition</i> , 2017, 35, 43-50.	1.1	39
165	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	2.0	11
166	Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2017, 58, 1068-1075.	0.6	20
167	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	2.5	76
168	Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic Leukemia. <i>Oman Medical Journal</i> , 2017, 32, 189-193.	0.3	0
169	Stem Cell Transplantation in Patients with Sickle Cell Disease. , 2016, , .		2
170	Patients with Lower Clearance of Busulfan Have Higher Risk of Graft Loss When Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S301.	2.0	0
171	Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 47, 22-25.	0.4	8
172	Novel therapeutic options in Acute Myeloid Leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 39-49.	0.2	30
173	Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1627-1636.	0.8	8
174	The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. <i>Tissue Engineering - Part A</i> , 2016, 22, 5-16.	1.6	11
175	Effects of the Sympathomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108.	0.6	4
176	Long-Term Iron Chelation Therapy with Deferiprone in Patients with Thalassemia Major and Low Iron Load. <i>Blood</i> , 2016, 128, 3626-3626.	0.6	1
177	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFCM-TC). <i>Blood</i> , 2016, 128, 4617-4617.	0.6	1
178	First Implementation of Transfusion Consent Policy in Oman: Audit of compliance from a tertiary care university hospital. <i>Sultan Qaboos University Medical Journal</i> , 2016, 16, e293-297.	0.3	1
179	Transfusion Consent in Oman: Physicians' Perception at a Tertiary Care University Hospital. <i>Oman Medical Journal</i> , 2016, 31, 253-257.	0.3	3
180	Reproducibility of Manual Platelet Estimation Following Automated Low Platelet Counts. <i>Oman Medical Journal</i> , 2016, 31, 409-413.	0.3	2

#	ARTICLE	IF	CITATIONS
181	Unusual Indolent Course of a Chronic Active Epstein-Barr Virus-Associated Natural Killer Cell Lymphoproliferative Disorder. Sultan Qaboos University Medical Journal, 2016, 16, e230-233.	0.3	0
182	Sickle Cell Disease Patients with Systemic Lupus Erythematosus Exhibit Quantitative and Qualitative Impairments in Circulating B Regulatory Cells. Blood, 2016, 128, 3641-3641.	0.6	1
183	Influence of Genetic Modifiers on Levels of Invariant Natural Killer T-Cells in Patients with Sickle Cell Anemia. Blood, 2016, 128, 4843-4843.	0.6	0
184	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4367-4367.	0.6	0
185	Genotype in Patients with Thalassemia Major Has No Impact on Risk of Liver Fibrosis. Blood, 2016, 128, 4835-4835.	0.6	0
186	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. Blood, 2016, 128, 4655-4655.	0.6	1
187	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. Blood, 2016, 128, 3497-3497.	0.6	0
188	Male Gender Increases the Risk of Liver Fibrosis in Patients with Thalassemia Major Independent of Iron Overload. Blood, 2016, 128, 3630-3630.	0.6	0
189	Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics and Proteomics, 2016, 13, 317-29.	1.0	22
190	Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents. Cancer Genomics and Proteomics, 2016, 13, 275-9.	1.0	1
191	Graft Versus Leukemia Effect Is Overestimated in Studies with High Rates of Graft Versus Host Disease Related Mortality: A Simulation Study. Biology of Blood and Marrow Transplantation, 2015, 21, S322-S323.	2.0	0
192	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. EBioMedicine, 2015, 2, 2101-2109.	2.7	36
193	Intraoperative cell salvage in cardiac surgery may increase platelet transfusion requirements: a cohort study. Vox Sanguinis, 2015, 109, 280-286.	0.7	12
194	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. British Journal of Haematology, 2015, 171, 585-594.	1.2	146
195	Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. Journal of Infectious Diseases, 2015, 212, 959-967.	1.9	63
196	Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia. Oman Medical Journal, 2015, 30, 111-114.	0.3	4
197	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematology, 2015, 2, e384-e392.	2.2	46
198	Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections. Journal of Infectious Diseases, 2015, 211, 1251-1261.	1.9	47

#	ARTICLE	IF	CITATIONS
199	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 499-508.	1.7	50
200	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. <i>British Journal of Haematology</i> , 2015, 169, 565-573.	1.2	104
201	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology</i> , 2015, 2, e91-e100.	2.2	329
202	Discriminatory power of the intraoperative cell salvage use in the prediction of platelet and plasma transfusion in patients undergoing cardiac surgery. <i>Transfusion and Apheresis Science</i> , 2015, 53, 208-212.	0.5	12
203	Safety of stem cell mobilization in donors with sickle cell trait. <i>Bone Marrow Transplantation</i> , 2015, 50, 310-311.	1.3	12
204	Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage. <i>American Journal of Clinical Pathology</i> , 2015, 144, 145-150.	0.4	9
205	Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic Children with Osteogenesis Imperfecta. <i>Sultan Qaboos University Medical Journal</i> , 2015, 15, e456-e462.	0.3	6
206	Travelling activity and travel-related risks after allogeneic haematopoietic stem cell transplantation – a single centre survey. <i>Swiss Medical Weekly</i> , 2015, 145, w14136.	0.8	1
207	Circulating Invariant Natural Killer T Cell Subsets Are Functionally Preserved in Splenectomized Children with Sickle Cell Disease Compared to Patients with Large Spleen. <i>Blood</i> , 2015, 126, 3389-3389.	0.6	0
208	Angiogenic markers in plasma cell myeloma patients treated with novel agents. <i>Anticancer Research</i> , 2015, 35, 1085-90.	0.5	8
209	Methemoglobinemia in an Elderly Patient with Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report. <i>Oman Medical Journal</i> , 2014, 29, 135-137.	0.3	11
210	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1574-1581.	1.7	73
211	The pneumatic tube system does not affect complete blood count results; a validation study at a tertiary care hospital. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 514-520.	0.7	14
212	Successful management of severe hemolytic disease of the fetus due to anti- α - A using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature. <i>Transfusion</i> , 2014, 54, 238-243.	0.8	14
213	Knowledge and Attitudes of Oman Medical Specialty Board Residents towards Evidence-Based Medicine. <i>Oman Medical Journal</i> , 2014, 29, 178-184.	0.3	9
214	Dkk3 levels in patients with myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2014, 133, 218-221.	0.8	2
215	Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. <i>Leukemia Research</i> , 2014, 38, 184-187.	0.4	11
216	Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 896-899.	2.0	78

#	ARTICLE	IF	CITATIONS
217	Response to Dr. Rice M and colleagues on their Letter to Editor regarding "Validation of a non-invasive pulse CO-oximetry based hemoglobin estimation in normal blood donors," Transfusion and Apheresis Science 2013 Nov 4. Accurate Enough for the Spectrum Tested. Transfusion and Apheresis Science, 2014, 51, 84-85.	0.5	1
218	Evaluation of the Pretransplantation Workup before Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1852-1856.	2.0	9
219	Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with β -Thalassemia Major. Hemoglobin, 2014, 38, 365-368.	0.4	10
220	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1841-1846.	2.0	53
221	Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo - Magazine of European Medical Oncology, 2014, 7, 206-210.	0.3	26
222	Transfusion indication predictive score: a proposed risk stratification score for perioperative red blood cell transfusion in cardiac surgery. Vox Sanguinis, 2014, 107, 269-275.	0.7	15
223	Safety of Stem Cell Mobilization in Donors with Sickle Cell Trait. Biology of Blood and Marrow Transplantation, 2014, 20, S214.	2.0	0
224	Validation of a non-invasive pulse CO-oximetry based hemoglobin estimation in normal blood donors. Transfusion and Apheresis Science, 2014, 50, 95-98.	0.5	21
225	A Rare Case of Congenital Atransferrinemia: International Collaboration for Genetic Diagnosis. Blood, 2014, 124, 4883-4883.	0.6	3
226	Liver Enzymes Changes and Safety Profile of Deferasirox Iron Chelator in Omani Children with Thalassemia Major. Blood, 2014, 124, 4903-4903.	0.6	2
227	Role of tumour angiogenesis in haematological malignancies. Swiss Medical Weekly, 2014, 144, w14050.	0.8	35
228	Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT. Blood, 2014, 124, 256-256.	0.6	0
229	Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT. Blood, 2014, 124, 2530-2530.	0.6	0
230	Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. Blood, 2014, 124, 185-185.	0.6	0
231	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. Blood, 2014, 124, 2570-2570.	0.6	0
232	Allogeneic Hematopoietic Stem Cells Transplantation for Non-Hodgkin's Lymphoma. The Swiss Experience 1985-2014. Blood, 2014, 124, 1256-1256.	0.6	0
233	Delivering a Hemophilic Newborn with No Intracranial Hemorrhage: Is Caesarian Section the Answer?. Blood, 2014, 124, 5060-5060.	0.6	0
234	Pseudopyropoikilocytosis leading to spurious results. Sultan Qaboos University Medical Journal, 2014, 14, e259-60.	0.3	1

#	ARTICLE	IF	CITATIONS
235	Recognition, Investigation and Management of Acute Transfusion Reactions: Consensus guidelines for Oman. Sultan Qaboos University Medical Journal, 2014, 14, e306-18.	0.3	1
236	Fetal outcomes in pregnant women with sickle cell disease. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 472-6.	0.5	2
237	Reply from the author. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1160.	0.5	0
238	A Single Daily Ultra Low-Dose of Oral Acyclovir Is Sufficient to Prevent the Occurrence of Herpes Zoster Post Hematopoietic Stem Cell Transplantation: Interim Results of a Prospective Randomized Trial. Biology of Blood and Marrow Transplantation, 2013, 19, S261-S262.	2.0	0
239	Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia with Busulfan-Based Reduced Intensity Conditioning: Cure and Fertility. Biology of Blood and Marrow Transplantation, 2013, 19, S285-S286.	2.0	1
240	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica, 2013, 98, 1282-1290.	1.7	110
241	Pulmonary valve regurgitation following balloon valvuloplasty for pulmonary valve stenosis: Single center experience. Annals of Pediatric Cardiology, 2013, 6, 141.	0.2	6
242	Validation of a noninvasive pulse oximetry-based hemoglobin estimation in patients with sickle cell disease. International Journal of Laboratory Hematology, 2013, 35, e21-3.	0.7	6
243	Maternal Complications and The Association with Baseline Variables in Pregnant Women with Sickle Cell Disease. Hemoglobin, 2013, 37, 219-226.	0.4	9
244	Concomitant microfilaria and malaria infection. Blood, 2013, 121, 4437-4437.	0.6	1
245	Extreme Preterm Premature Rupture of Membranes: Risk Factors and Feto Maternal Outcomes. Oman Medical Journal, 2013, 28, 108-111.	0.3	22
246	Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. Oman Medical Journal, 2013, 28, 121-124.	0.3	38
247	The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party. Blood, 2013, 122, 922-922.	0.6	9
248	Perinatal Outcome in Pregnancies with Extreme Preterm Premature Rupture of Membranes () Tj ETQq0 0 0 rgBT /Overlock 10,Tf 50 222	0.3	9
249	Perinatal Outcome of Monochorionic in Comparison to Dichorionic Twin Pregnancies. Oman Medical Journal, 2013, 28, 173-177.	0.3	16
250	Genital Ulcer Development in Patients with Acute Promyelocytic Leukaemia Treated with All-Trans Retinoic Acid: A Case Series. Oman Medical Journal, 2013, 28, 207-209.	0.3	6
251	Evaluation Of The Pre-Transplantation Workup Before Allogeneic Transplantation and Reasons For Delaying Or Cancelling Transplant. Blood, 2013, 122, 5456-5456.	0.6	1
252	Intra-Arterial Catheter Guided Steroid Administration For The Treatment Of Steroid-Refractory Intestinal GvHD. Blood, 2013, 122, 4604-4604.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Pulmonary Hypertension in Sickle Cell Disease: Correlation With Echocardiographic Assessment and Serum Brain Natriuretic Peptide Concentration. <i>Blood</i> , 2013, 122, 4680-4680.	0.6	0
254	Outcome Of Aplastic Anemia In Adolescence. A Survey Of The Severe Aplastic Anemia Working Party (SAAWP) Of The European Blood and Bone Marrow Transplant Group (EBMT). <i>Blood</i> , 2013, 122, 2481-2481.	0.6	0
255	Negative Impact Of KIR/HLA Interactions On NK Cell Activity Can Be Overcome By The Glycoengineered Antibody CA101 (Obinutuzumab). <i>Blood</i> , 2013, 122, 376-376.	0.6	12
256	Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 18-28.	3.0	74
257	Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. <i>Journal of Human Genetics</i> , 2012, 57, 665-669.	1.1	25
258	T2* MRI in Regularly Transfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect Liver Iron Stores. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 579-584.	0.3	14
259	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. <i>Chest</i> , 2012, 142, 988-995.	0.4	17
260	Validation of a Non-Invasive Hemoglobin Estimation in Patients with Sickle Cell Disease. <i>Blood</i> , 2012, 120, 4770-4770.	0.6	1
261	Non-Invasive Hemoglobin Estimation in Patients with β^0 -Thalassemia Major. <i>Blood</i> , 2012, 120, 5179-5179.	0.6	0
262	Heparin Does Not Increase Live Births in Pregnant Women with Previous Unexplained Recurrent Miscarriages: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2012, 120, 504-504.	0.6	0
263	Validation of a Non-Invasive Hemoglobin Estimation in Whole Blood Donors.. <i>Blood</i> , 2012, 120, 2280-2280.	0.6	12
264	Long Term Outcomes of Allogeneic Transplant Using Non-Radiation Based Preparative Regimens for Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S313.	2.0	0
265	Long Term Follow up of Patients with Immune Thrombocytopenia Receiving Rituximab. <i>Blood</i> , 2011, 118, 4675-4675.	0.6	1
266	Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major. <i>Blood</i> , 2011, 118, 5294-5294.	0.6	0
267	T2* MRI in Hypertransfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect the Reality. <i>Blood</i> , 2011, 118, 5304-5304.	0.6	0
268	Gonadal Function In Patients with Beta-Thalassemia Major Following Bone Marrow Transplantation,. <i>Blood</i> , 2011, 118, 4105-4105.	0.6	0
269	Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 61-65.	0.6	20
270	Prevalence of Thrombophilia In Patients with Sickle Cell Disease and Osteonecrosis. <i>Blood</i> , 2010, 116, 3184-3184.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Validation of Monosomal Karyotype Based Model In the Risk Stratification of Acute Myeloid Leukemia. Blood, 2010, 116, 2745-2745.	0.6	0
272	Inherited Thrombophilia In Omani Women with Recurrent Pregnancy Loss. Blood, 2010, 116, 5124-5124.	0.6	0
273	A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia. Blood, 2010, 116, 2730-2730.	0.6	0
274	Combined Corticosteroid and Antiviral Treatment for Bell Palsy. JAMA - Journal of the American Medical Association, 2009, 302, 985.	3.8	140
275	Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation.. Blood, 2009, 114, 1202-1202.	0.6	0
276	High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Primary Therapy of Advanced Follicular Lymphoma in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.. Blood, 2009, 114, 2314-2314.	0.6	1
277	Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction Chemotherapy. Acta Haematologica, 2008, 120, 5-10.	0.7	14
278	Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols. Blood, 2008, 112, 3956-3956.	0.6	0
279	Myeloid-Associated Antigen Expression Is an Adverse Factor for Complete Remission Following Induction Chemotherapy of Adult Precursor T-Lymphoblastic Leukemia/Lymphoma (T-ALL).. Blood, 2007, 110, 4228-4228.	0.6	0
280	Abandoning Care in Laminar Air Flow (LAF) Units and Routine High Dose Intravenous Immunoglobulines (IVIg) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Does Not Increase Mortality and Rate of Infections.. Blood, 2004, 104, 5072-5072.	0.6	2
281	Late Mortality Following Allogeneic Stem Cell Transplantation Is Closely Associated with Chronic Graft Versus Host Disease but Not with Donor Type.. Blood, 2004, 104, 56-56.	0.6	3